X4 PHARMACEUTICALS, INC.
XFOR US98420X1037
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -65% | -62% | -13% | -17% | -1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Baldry Mark CCO |
2.48 USD |
1,032 Bought |
2,561 USD |
16/05/2025 | 16/05/2025 |
| Ragan Paula CEO |
0.45 USD |
76,473 Sold |
34,719 USD |
23/01/2025 | 24/01/2025 |
| Baldry Mark CCO |
0.45 USD |
29,159 Sold |
13,241 USD |
23/01/2025 | 24/01/2025 |
| Mostafa Adam S. CFO |
0.45 USD |
74,773 Sold |
33,947 USD |
23/01/2025 | 24/01/2025 |
| Arbet-engels Christophe CMO |
0.45 USD |
11,624 Sold |
5,284 USD |
23/01/2025 | 24/01/2025 |
| Dibiase Mary COO |
0.45 USD |
22,258 Sold |
10,094 USD |
23/01/2025 | 24/01/2025 |
| Ragan Paula CEO |
0.39 USD |
31,897 Sold |
12,583 USD |
15/11/2024 | 15/11/2024 |
| Baldry Mark CCO |
0.34 USD |
13,404 Bought |
4,598 USD |
17/05/2024 | 15/11/2024 |
| Ragan Paula CEO |
0.39 USD |
31,897 Sold |
12,583 USD |
15/11/2024 | 15/11/2024 |
| Ragan Paula CEO |
0.56 USD |
31,897 Sold |
17,926 USD |
15/10/2024 | 15/10/2024 |